Burbano 2002 USA.

Methods	Country: USA Setting: community‐based clinic Duration of recruitment: 1998 to 2000 Duration of follow‐up: 12 months Design: randomized placebo‐controlled trial
Participants	Inclusion criteria: confirmed HIV, past or present use of illegal drugs, ≥ 18 years, adequate selenium status (> 85 µg/L) Exclusion criteria: selenium deficient (< 85 µg/L) Participants randomized: 259 112 female Median age = 40 years (range 24 to 54) Loss to follow‐up/withdrawal: 73 at 12 months Exclusions postrandomization: 0
Interventions	200 microgram selenium or placebo daily for 12 months.
Outcomes	Primary outcomes Number of hospital admissions Type of hospital admissions Risk of hospitalization Secondary outcomes CD4 count Hospitalization cost Plasma selenium
Adverse events	None reported
Notes	Number of participants on ART: Selenium group: 64 (76%) Control group: 60 (53%) Number, type, and duration of hospital admissions recorded 2 years prior and during study period. Medical records reviewed by team of physicians. Source of funding: research grant and commercial (materials)
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	The trial authors did not describe how they performed sequence generation.
Allocation concealment (selection bias)	Unclear risk	The trial authors did not describe how they performed allocation concealment.
Blinding (performance bias and detection bias) All outcomes	Low risk	Participants and investigators were blinded.
Incomplete outcome data (attrition bias) All outcomes	High risk	Exclusions from the analysis (73/259 (28%)) not reported by treatment group.
Selective reporting (reporting bias)	Unclear risk	Insufficient information; the trial protocol was unavailable
Other bias	Unclear risk	The trial authors did not declare on any conflicts of interest, if any.